Article
Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up.
Annals of oncology : official journal of the European Society for Medical Oncology - 1 Jan 2017
Kadara H, Choi M, Zhang J, Parra E R, Rodriguez-Canales J, Gaffney S G, Zhao Z, Behrens C, Fujimoto J, Chow C, Yoo Y, Kalhor N, Moran C, Rimm D, Swisher S, Gibbons D L, Heymach J, Kaftan E, Townsend J P, Lynch T J, Schlessinger J, Lee J, Lifton R P, Wistuba I I, Herbst R S
Abstract excerpt
Background: Lung adenocarcinomas (LUADs) lead to the majority of deaths attributable to lung cancer. We performed whole-exome sequencing (WES) and immune profiling analyses of a unique set of clinically annotated early-stage LUADs to better understand the pathogenesis of this disease and identify clinically relevant molecular markers. Methods: We performed WES of 108 paired stage I-III LUADs and normal lung...
Topics
- Adenocarcinoma
- Adenocarcinoma of Lung
- Biomarkers, Tumor
- DNA Mutational Analysis
- Disease-Free Survival
- Exome
- Female
- Follow-Up Studies
- Genome-Wide Association Study